Verified employee & interview reviews

Takeda Reviews

Tokyo, Japan

5.0/ 5

3 reviews

Takeda Pharmaceutical Company Limited is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Tokyo, Japan, with its historic roots in Osaka dating back to 1781 when it was founded by Chobei Takeda. Incorporated in January 1925, the company has grown from a traditional medicines business into one of the top 20 largest pharmaceutical companies in the world and the third largest in Asia by revenue. It employs nearly 50,000 people globally and operates commercial networks, manufacturing centers, and research hubs across six continents, with significant operations in the United States, Europe, and Canada alongside its home market of Japan. Takeda’s corporate strategy centers on the discovery, development, and delivery of highly differentiated specialty medicines and vaccines, intentionally avoiding a broad primary-care model. Its core commercial and clinical operations are organized across several major therapeutic business segments: gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and targeted vaccines. The company’s modern profile and global scale were significantly transformed following its historic $62 billion acquisition of Shire in 2019, which heavily expanded Takeda’s presence and capabilities in rare genetic disorders and immunology. This supplemented previous strategic expansions, including the acquisitions of Millennium Pharmaceuticals in 2008, Nycomed in 2011, and Ariad Pharmaceuticals in 2017. A distinguishing feature of Takeda's operational model is its massive plasma-derived therapies business, which introduces unique manufacturing, infrastructure, and supply-chain dimensions relative to conventional pharmaceutical portfolios. The company maintains an extensive, modality-diverse pipeline spanning small molecules, complex biologics, and plasma products, with major global research and development centers located in Cambridge (Massachusetts), San Diego (California), and Shonan (Japan). Takeda selectively utilizes strategic partnerships and in-licensing—such as the MIT-Takeda Program for artificial intelligence in healthcare—to supplement internal R&D and share development risks. Financially, Takeda is publicly traded on both the Tokyo Stock Exchange and the New York Stock Exchange (ticker: TAK). The company focuses on capital allocation that prioritizes funding its innovative late-stage pipeline, managing debt down post-merger, and mitigating generic erosion on older products through new launch rollouts, such as Zasocitinib and Oveporexton. Takeda operates under a distinct management philosophy using a decision hierarchy of Patient-Trust-Reputation-Business to guide long-term governance. Structurally, the company is led by President and CEO Christophe Weber, with Julie Kim designated as the successor to step into the chief executive role.